Back to catalogue
№ 158 38 filings · 2021-04-19 → 2026-05-11

TRUFIN PLC

TRU
Financial Services Market cap £127m Overall fit 340 /1000

Quality smallcap with genuine operating leverage and disciplined capital allocation, but minimal AI-receiver exposure (Oxygen's AI-data-analytics is a minor feature, Playstack and Satago are not AI plays), so it scores poorly against the investor's primary pillar despite fair valuation and decent downside protection.

Fair value range 134p–174p Mid case · £150m
Absolute upside +18.4% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • clean disclosure and segmental detail across three subsidiaries
  • consistent track record of beating guidance over 2024-2025
  • two valuation approaches (SoTP, PE multiple) converge near £150m
Limits the call
  • Playstack value is swing factor and games-publisher multiples are wide-ranging (5-15x EBITDA)
  • hit-driven gaming revenue not cleanly extrapolatable beyond 2026
Methodology

Sum-of-parts EBITDA multiples cross-checked vs forward PE

In one line · bull case

Three-business AIM smallcap with demonstrated operating leverage and disciplined buybacks at a ~15-20% discount to sum-of-parts fair value, driven primarily by an award-winning games publisher with proven hit-discovery process.

In one line · biggest risk

Playstack's 2024-2025 outperformance was hit-driven (Balatro, Abiotic Factor) and the base-effect makes 2027+ comps difficult absent Mortal Shell II commercial success.

Drivers
AI beneficiary 22 /100
Oxygen mentions AI-enabled data capture in its Insights product but it is not a primary value driver; Playstack and Satago have no direct AI-receiver exposure.
Operating leverage 60 /100
Group level leverage delivered EBIT +699% on revenue +20% in 2025, but step-change came from crossing breakeven; subsidiary-level leverage is more moderate going forward.
Earnings vs expectations 78 /100
Multiple upgrades during 2024 and 2025, with consistent beats vs. guidance at trading updates and final results.
Growth momentum 70 /100
Revenue grew 20% in 2025 with PBT +848%; early 2026 trading in line with expectations and pipeline of 8 Playstack titles plus Oxygen contracted growth.
Moat 50 /100
Oxygen has 100% retention and 7.7-year avg tenure (real moat); Playstack has process moat in game discovery but hit-driven industry; Satago lost its anchor contract once already.
Earnings quality 62 /100
Reported profit benefits from deferred tax credits (£3.9m credit on £7.6m PBT in 2025); cash generation is robust and adjusted measures broadly track GAAP.
Management quality 70 /100
Disciplined capital allocation framework, three buybacks in 12 months at IV discount, rejected unsolicited Oxygen bid in Dec 2022, exited Vertus when value crystallised.
Cyclicality 50 /100
Games publishing is hit-driven (mid-cyclical), Oxygen serves public sector (low cyclicality), Satago is fintech (moderate); net moderate.
Leverage 12 /100
Net cash position with £12.4m cash and effectively zero borrowings.

TRUFIN PLC (TRU) — Investment Research Note

Executive summary

TruFin is an AIM-listed Jersey holding company with three operating subsidiaries — Playstack (games publishing, ~84% of group revenue), Oxygen (UK public-sector early-payment and procurement SaaS), and Satago (invoice-finance LaaS) — that has transitioned from a loss-making lending vehicle in 2021 to a 20%-growing, cash-generative group with FY25 adjusted EBITDA of £12.6m and adjusted PBT of £8.4m 2026-03-18 final results. The Group has executed two share buybacks totalling £8m at avg 106p during 2025 plus a third £6m programme launched 23 Jan 2026, with management citing a "discount to intrinsic value". The single most important valuation point: TRU is now a games-publisher-plus-bits, and Playstack — which delivered £55.3m revenue and £12.2m PBT in 2025 (revenue +24%) — drives the rerating thesis, with the risk that 2024-25 Balatro/Abiotic Factor outperformance proves hard to repeat.

Fair value estimate

Methodology: Sum-of-parts, given three structurally distinct businesses.

  • Playstack (£13.5m EBITDA, £12.2m PBT 2025; "hit ratio" >85%, ROIDC >300%): 7–9x EBITDA = £95–£122m (games publishers trade at a discount to software given hit-driven revenue volatility; back-catalogue now ~50% of 2026 expected revenue gives some recurring quality)
  • Oxygen (£9.1m revenue, £3.8m EBITDA, £2.1m EBIT 2025; 100% retention, 7.7-yr avg tenure, 98% of 2026 EP revenue from existing clients): 11–13x EBITDA = £42–£49m
  • Satago (£1.2m revenue, still loss-making but targeting breakeven June 2026, subscription rev +69% YoY, recent 140% growth in Jan-Feb 2026): nominal £3–8m
  • Less: central holding costs of ~£3m/yr capitalised at 7x = –£20m
  • Plus: year-end cash £12.4m, minimal borrowings (~zero)

Fair value range: £132m–£171m equity value, mid ~£150m Per share: 134p–174p, mid ~152p (basis 98.66m shares; further reduced by ongoing £6m buyback)

Versus current market cap of £127.2m (~129p):

  • Upside to mid: ~+18%
  • Range vs current: -2% to +35%

A cross-check using adjusted PBT of £8.4m × 17–20x (justified by 20% growth and net cash) yields £143–168m — broadly consistent.

Sector context

ICB classification as Financial Services is technically correct (the group started as a fintech and Satago/Oxygen sit in financial services), but functionally TRU is now ~84% a video-games publisher. Listed peers split across:

  • Games publishers: Devolver Digital (DEVO LN), Team17 (TM17 LN), Frontier Developments (FDEV LN) — Playstack's hit ratio and ROIDC profile compare favourably
  • Public-sector procurement SaaS: no clean UK comp; Tracsis (TRCS LN) the loose analogue for Oxygen
  • Fintech invoice finance: Time Finance (TIME LN), Distribution Finance Capital (DFCH LN — TruFin's own former subsidiary)

Quality is above typical financial-services smallcaps (net cash, growing, profitable, disciplined capital allocation); growth is above typical games-publisher peers in 2025; but cyclical/hit-driven risk is higher than the conglomerate's SoTP structure suggests.

Investment thesis (3 bullets)

  1. Demonstrated operating leverage post-breakeven, with the holding-co cost base now levered. FY24→FY25 saw revenue +20% but adjusted EBIT +699%, and the CEO explicitly highlights "embedded operational leverage". With central costs largely fixed and Oxygen's 98% of forward revenue contracted, incremental Playstack hits drop hard to the bottom line 2026-03-18 final results.

  2. Disciplined capital return at an explicit IV discount. Three buybacks in 12 months (£14m aggregate, at avg ~106p) signal management conviction that intrinsic value exceeds market — and shrink the share count for remaining holders. The CEO has clearly articulated a capital-allocation framework that prioritises high-return organic spend, then buybacks below intrinsic, rather than ego-driven M&A 2026-03-18 final results, 2026-01-15 trading update.

  3. Repeated beats in 2024–2025 build credibility on the upgrade cadence. The 11 Dec 2025 and 15 Jan 2026 trading updates both raised guidance ahead of the eventual print (revenue £63m → £65.9m; PBT £7.4m → £8.4m), and Oxygen alone delivered 18% revenue growth despite Procurement Act disruption 2025-12-11, 2026-01-15, 2026-03-18.

Key risks (3 bullets)

  1. Balatro/Abiotic Factor base-effect risk for Playstack 2026. Balatro alone has won three Game Awards (2024) and contributed materially to back-catalogue performance; back-catalogue is expected to be ~50% of Playstack's 2026 revenue. Once the launch wave normalises, console revenue can step down sharply — gaming is an inherently hit-driven category and the £35.4m PBT base in central forecasts may not repeat in 2027 without Mortal Shell II commercial success 2025-12-11 trading update.

  2. Customer concentration / contract-loss precedent at Satago. The Lloyds tier-1 contract loss in July 2024 cratered Satago revenue from £3.8m to £1.2m (–68% over two years) and reminds the market that "platform-of-choice" wins can reverse. Satago carries goodwill (~£0.8m in CGU) plus £8.5m internally generated software at risk if recovery stalls — 20% growth-rate sensitivity already flagged in note 10 of the accounts 2026-03-18 final results, note 10.

  3. Procurement Act drag on Oxygen plus AIM-smallcap liquidity. The 2025 Procurement Act delayed local-government supplier onboarding (Oxygen H2 2025 growth slowed to 12% YoY), and although management expects normalisation, regulatory transitions in public sector can persist. AIM listing + Jersey incorporation + multiple insider/strategic holdings (Watrium ~23%, Gresham ~12%) limit free float 2025-09-17 H1 results, 2023-06-23 placing announcement.

Operating leverage

TRU has genuine but increasingly mature operating leverage. The Group cost base is dominated by staff (£13.3m of £35m net cost base in 2025) and amortisation of internally developed software (~£4m). With central holding costs of ~£3.3m running near-flat as revenue scaled from £18m (2023) to £66m (2025), the holdco was the swing factor in the PBT explosion — adjusted EBIT grew 699% YoY 2026-03-18 CEO review. Subsidiary-level leverage is more moderate: Playstack's EBITDA grew 20% on 24% revenue (publishing royalties scale roughly with revenue), and Oxygen's 67% EBITDA growth on 18% revenue is the cleanest SaaS-style leverage (gross margin ~88% on EP contracts). On a 10–20% revenue beat from here, I'd expect EBITDA to outgrow by roughly 1.5–2.0x — so a 20% upside revenue surprise probably yields ~£20m EBITDA vs. £12.6m base, not a multiple of profit. The marginal-leverage step-change has already happened in 2024→2025.

Value-trap signals

None identified that suggest structural cheapness. Revenue is growing 20%, balance sheet is net cash, no dividend cuts (none paid), no material related-party transactions of concern, no regulatory threats beyond the bedding-in Procurement Act. Satago contract loss was a one-off customer event, not a structural issue. The discount to my fair-value mid is modest (~18%) and consistent with AIM smallcap liquidity discounting rather than a value trap.

Earnings vs. expectations

The 2024–2025 cadence is one of repeated upgrades:

  • FY24 (Mar 2025 results): Beat — original 2024 expectations had been for modest profitability; actual PBT £0.9m delivered "a year earlier than anticipated"
  • H1 2025 (Sept 2025): Beat — revenue +42%, PBT +2,711%; "materially exceed market expectations for the full year"
  • Trading update 11 Dec 2025: Raised FY25 guidance to PBT >£7.0m
  • Trading update 15 Jan 2026: Raised again to PBT >£7.4m
  • FY25 (March 2026 results): Beat — actual adjusted PBT £8.4m vs. £7.4m guided

Pattern: consistent material beats vs. guidance. Management appears to set deliberately conservative numbers and then upgrade through the year, which the market is starting to recognise (share price up >400% from mid-2020 trough per CEO commentary).

Conviction: 3 (moderate)

Supports: clean audited financials with detailed segmental disclosure; track record of meeting/beating guidance; multiple converging valuation approaches (SoTP ~£150m, PE-based ~£155m) land in similar range; cash-generative with simple balance sheet.

Limits: Playstack value is the swing factor and games-publisher multiples are notoriously variable (5x–15x EBITDA range observable across peers); hit-driven category means historical results may not extrapolate cleanly to 2027+; AIM mid-cap with limited analyst coverage and no obvious cross-check from sell-side consensus disclosed in filings.

Filings consulted · 46

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-11Notice OF Agm2026-05-11_9562488_notice-of-agm.md0.30
  2. 2026-03-18Final Results For The 12 Months Ended 31 Dec 20252026-03-18_9479251_final-results-for-the-12-months-ended-31-dec-2025.md1.00
  3. 2026-03-05Notice OF Results And Investor Presentation2026-03-05_9459348_notice-of-results-and-investor-presentation.md0.70
  4. 2026-01-15Trading Update2026-01-15_9354432_trading-update.md0.85
  5. 2025-12-11Trading Update2025-12-11_9289197_trading-update.md0.85
  6. 2025-09-17Half Year Report2025-09-17_9112447_half-year-report.md0.77
  7. 2025-08-14Trading Update2025-08-14_9051858_trading-update.md0.72
  8. 2025-06-12Result OF Agm2025-06-12_8926466_result-of-agm.md0.26
  9. 2025-05-20Trading Update And Share Buyback2025-05-20_8886270_trading-update-and-share-buyback.md0.72
  10. 2025-05-13Notice OF Agm2025-05-13_8874007_notice-of-agm.md0.20
  11. 2025-03-26Final Results For The 12 Months Ended 31 Dec 20242025-03-26_8797114_final-results-for-the-12-months-ended-31-dec-2024.md0.65
  12. 2025-03-19Notice OF Results And Investor Presentation2025-03-19_8785887_notice-of-results-and-investor-presentation.md0.46
  13. 2025-01-06Trading Statement2025-01-06_8647127_trading-statement.md0.55
  14. 2024-12-05Trading Statement2024-12-05_8591372_trading-statement.md0.55
  15. 2024-11-18Trading Statement2024-11-18_8555181_trading-statement.md0.55
  16. 2024-09-17Half Year Report2024-09-17_8419771_half-year-report.md0.58
  17. 2024-08-29Notice OF Interim Results Amp Investor Presentation2024-08-29_8389036_notice-of-interim-results-amp-investor-presentation.md0.58
  18. 2024-06-05Result OF Agm2024-06-05_8243726_result-of-agm.md0.20
  19. 2024-05-13Trading Statement2024-05-13_8190821_trading-statement.md0.38
  20. 2024-05-02Notice OF Agm2024-05-02_8171644_notice-of-agm.md0.14
  21. 2024-03-26Final Results For The 12 Months Ended 31 Dec 20232024-03-26_8106167_final-results-for-the-12-months-ended-31-dec-2023.md0.45
  22. 2024-03-19Notice OF Results And Investor Presentation2024-03-19_8094080_notice-of-results-and-investor-presentation.md0.32
  23. 2024-02-08Trading Update2024-02-08_8027602_trading-update.md0.38
  24. 2024-01-04Trading Update2024-01-04_7973999_trading-update.md0.38
  25. 2023-11-09Oxygen Finance Acquisition OF Bidstats UK2023-11-09_7869799_oxygen-finance-acquisition-of-bidstats-uk.md0.34
  26. 2023-09-29Half Year Report2023-09-29_7785461_half-year-report.md0.41
  27. 2023-09-28Result OF Agm2023-09-28_7784187_result-of-agm.md0.14
  28. 2023-08-29Notice OF Agm2023-08-29_7723428_notice-of-agm.md0.14
  29. 2023-07-10Result OF GM And Result OF Placing And Open Offer2023-07-10_7623150_result-of-gm-and-result-of-placing-and-open-offer.md0.32
  30. 2023-06-23Result OF Placing And Notice OF General Meeting2023-06-23_7590232_result-of-placing-and-notice-of-general-meeting.md0.32
  31. 2023-06-22Proposed Placing And Open Offer2023-06-22_7589677_proposed-placing-and-open-offer.md0.32
  32. 2023-03-15Final Results For The Year Ended 31 December 20222023-03-15_7436465_final-results-for-the-year-ended-31-december-2022.md0.25
  33. 2023-01-20Statement Regarding Satago And Trading Update2023-01-20_7471507_statement-regarding-satago-and-trading-update.md0.21
  34. 2022-10-10Notice OF Capital Markets Day2022-10-10_7255719_notice-of-capital-markets-day.md0.24
  35. 2022-09-20Interim Results2022-09-20_7369379_interim-results.md0.23
  36. 2022-09-12Notice OF Capital Markets Day2022-09-12_7273899_notice-of-capital-markets-day.md0.24
  37. 2022-06-07Result OF Agm2022-06-07_7113425_result-of-agm.md0.07
  38. 2022-05-04Notice OF Agm2022-05-04_7192591_notice-of-agm.md0.07
  39. 2022-04-29Final Results For The Year Ended 31 December 20212022-04-29_7089967_final-results-for-the-year-ended-31-december-2021.md0.25
  40. 2022-04-11Result OF GM And Result OF Placing And Open Offer2022-04-11_6905098_result-of-gm-and-result-of-placing-and-open-offer.md0.17
  41. 2022-03-23Result OF Placing And Notice OF General Meeting2022-03-23_7006214_result-of-placing-and-notice-of-general-meeting.md0.17
  42. 2022-03-22Proposed Placing And Open Offer2022-03-22_7005983_proposed-placing-and-open-offer.md0.17
  43. 2021-12-10Statement Regarding Satago And Trading Update2021-12-10_6796098_statement-regarding-satago-and-trading-update.md0.21
  44. 2021-09-29Interim Results2021-09-29_6595100_interim-results.md0.23
  45. 2021-06-08Result OF Agm2021-06-08_6620915_result-of-agm.md0.07
  46. 2021-04-19Final Results For The Year Ended 31 December 20202021-04-19_6532479_final-results-for-the-year-ended-31-december-2020.md0.10

This research note was authored by a large language model after reading 38 regulatory filings published between 2021-04-19 and 2026-05-11. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.